Results 91 to 100 of about 46,971 (258)

Update on the success of the pneumococcal conjugate vaccine

Paediatrics & Child Health, 2011
Several years after the seven-valent pneumococcal conjugate vaccine (PCV7) was introduced in Canada and elsewhere, routine infant vaccination has led to near eradication of invasive pneumococcal disease caused by vaccine serotype strains in both children and adults.
openaire   +3 more sources

Experience with pneumococcal conjugate vaccine in Norway

Expert Review of Vaccines, 2009
Seven-valent pneumococcal conjugate vaccine (PCV7) was introduced into the Norwegian childhood vaccination program in July 2006 in a 2+1 dose (three-dose) schedule. Vaccine coverage quickly reached high levels and the incidence rate of invasive pneumococcal disease in children under 2 years of age declined rapidly.
openaire   +3 more sources

Rapid replacement by non-vaccine pneumococcal serotypes may mitigate the impact of the pneumococcal conjugate vaccine on nasopharyngeal bacterial ecology

Scientific Reports, 2017
There is growing concern that interventions that alter microbial ecology can adversely affect health. We characterised the impact of the seven-valent pneumococcal conjugate vaccine (PCV7) on pneumococcal carriage and the bacterial component of the ...
B. Kwambana-Adams, B. Hanson, A. Worwui, S. Agbla, E. Foster-Nyarko, Fatima Ceesay, Chinelo Ebruke, U. Egere, Yanjiao Zhou, Maze Ndukum, E. Sodergren, M. Barer, R. Adegbola, G. Weinstock, M. Antonio   +14 more
semanticscholar   +1 more source

Estimated severe pneumococcal disease cases and deaths before and after pneumococcal conjugate vaccine introduction in children younger than 5 years of age in South Africa

PLoS ONE, 2017
Introduction Streptococcus pneumoniae is a leading cause of severe bacterial infections globally. A full understanding of the impact of pneumococcal conjugate vaccine (PCV) on pneumococcal disease burden, following its introduction in 2009 in South ...
C. von Mollendorf, S. Tempia, A. von Gottberg, S. Meiring, V. Quan, C. Feldman, J. Cloete, S. Madhi, K. O'Brien, K. Klugman, C. Whitney, C. Cohen   +11 more
semanticscholar   +1 more source

SAFETY AND IMMUNOGENICITY OF TWO LOTS OF PNEUMOCOCCAL CONJUGATE VACCINE IN INFANTS. ▴ 1116 [PDF]

, 1996
Kenneth M. Zangwill, David P. Greenberg, Victor K. Wong, S-J Chang, Susan Partridge, Joel I. Ward   +5 more
openalex   +1 more source

Clinical and bacteriological characteristics of invasive pneumococcal disease after pneumococcal 10-valent conjugate vaccine implementation in Salvador, Brazil

Brazilian Journal of Infectious Diseases, 2016
Invasive pneumococcal disease is a relevant public health problem in Brazil, especially among children and the elderly. In July/2010 a 10-valent pneumococcal conjugate vaccine was introduced to the immunization schedule of Brazilian children under two ...
Carolina Regis Leite, Jailton Azevedo, Vivian Santos Galvão, Otávio Moreno-Carvalho, Joice Neves Reis, Cristiana Nascimento-Carvalho   +5 more
doaj  

IMMUNOGENICITY OF A PNEUMOCOCCAL PROTEIN CONJUGATE VACCINE IN INFANTS WITH SICKLE CELL DISEASE. ▴ 946 [PDF]

, 1996
Katherine L. O’Brien, Jerry A. Winkelstein, Mathuram Santosham, Andrea J. Swift, George J. Dover, Allen E. Eskenazi, Ruth E. Luddy, Archie S. Golden, Joseph E. Gootenberg, Frank Malinoski, Howard M. Lederman   +10 more
openalex   +1 more source

Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children

Journal of Immunology Research, 2015
Applications of the heptavalent pneumococcal conjugate vaccine (PCV7) in the pediatric immunization schedule have dramatically reduced the incidence of pneumococcal diseases in both vaccinated children and unvaccinated individuals of all ages.
Susanna Esposito, Nicola Principi
doaj   +1 more source

Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England

PLoS ONE, 2016
Background Recently a large clinical trial showed that the use of 13-valent pneumococcal conjugate vaccine (PCV13) among immunocompetent individuals aged 65 years and over was safe and efficacious.
A. V. van Hoek, E. Miller
semanticscholar   +1 more source

Serum Opsonic Activity for Streptococcus pneumoniae Types 6B and 14 in Infants with Sickle Cell Disease after Immunization with Pneumococcal Protein Conjugate Vaccine [PDF]

, 1999
Anna Nowak‐Węgrzyn, Jerry A. Winkelstein, Beth Stover, Andrea J. Swift, Howard M. Lederman   +4 more
openalex   +1 more source